divozilimab

Synonyms: BCD 132 | BCD-132 | Ivlizi®

divozilimab is an approved drug (Russia (2023))

Compound class: Antibody

Comment: Divozilimab (BCD 132) is an anti-CD20 monoclonal antibody that was developed by Biocad.

Immunopharmacology Comments
Divozilimab is intended to block immune system-mediated damage to nervous tissues in multiple sclerosis, that is caused by CD20-expressing B cells.

Immunopharmacology Comments

Divozilimab is intended to block immune system-mediated damage to nervous tissues in multiple sclerosis, that is caused by CD20-expressing B cells.